Alternative image
SHARE
Press Release
Back
Products

2026-08-18

Evonik provides customers with Life Cycle Assessment data for selected EUDRAGIT® polymers

Evonik now provides Life Cycle Assessment data for selected EUDRAGIT® polymers. This helps pharmaceutical customers measure environmental impacts. It also helps them compare formulation options with sustainability criteria. The data covers selected oral drug delivery grades. It includes climate change potential, water consumption, and fossil resource use. The calculations follow recognized standards. They were reviewed by an external expert. Customers can request the datasets and use them in their own product sustainability assessments.

  • Evonik now offers LCA data for selected EUDRAGIT® polymers to support pharmaceutical sustainability assessments and formulation decisions.
  • The environmental data helps pharmaceutical customers quantify impacts and compare formulation options using sustainability criteria.
  • The LCA scope includes selected oral drug delivery grades and indicators such as climate impact, water use, and fossil resources.
  • Evonik states the calculations follow recognized standards and were critically reviewed by an external expert.
  • Customers can request the datasets and integrate them into their own product sustainability assessments.
  • TÜV-certified Life Cycle Assessment (LCA) methodology supports customers’ Scope 3 emissions reporting
  • EUDRAGIT® L 100-55 shows around 6 percent reduction in product carbon footprint (PCF) due to improvement measures
  • Supports the 2030 sustainability targets and commitments for Evonik’s Health Care business

Evonik now offers its customers cradle-to-gate LCA data for selected EUDRAGIT® functional polymers. These results are derived from Evonik’s TÜV-certified LCA method. This data supports customers’ Scope 3 emissions (indirect emissions) reporting and underscores Evonik’s commitment to greater transparency across the value chain. LCA data is currently available for EUDRAGIT® L 100-55 and EUDRAGIT® L 30 D-55, with further grades expected to follow in early 2027.

“Our customers need credible sustainability data they can trust and use,” said Thilo Krapfl, head of the Oral Drug Delivery Solutions product line at Evonik. “Life cycle assessments enable us and our customers to make data-driven decisions that improve the sustainability profile of pharmaceutical products and processes."

Pharmaceutical companies are facing increasing pressure to reduce their Scope 3 emissions and meet evolving environmental, social and governance (ESG) requirements. As a result, customers increasingly seek suppliers who offer transparent environmental data and demonstrate efforts to reduce emissions across the value chain.

Cradle-to-gate LCAs evaluate the environmental impact of a product from raw material extraction through production. LCA data from Evonik's certified LCA methodology helps pharmaceutical companies understand the footprint of excipients, and leverage opportunities to reduce environmental impacts across the value chain.

In the case of EUDRAGIT® L 100-55, the implementation of a state-of-the-art spray drying system at Evonik's Darmstadt site resulted in approximately 6 percent reduction in the PCF compared to the previous set-up. The new spray drying facility is powered by renewable electricity, and its location minimizes transport between production sites.

“Sustainability is a continuous improvement journey,” said Muhammad Irfan, Plant Production Manager at Evonik Health Care. “By using LCA data to identify hotspots, we can focus our improvement efforts where they have the greatest impact – from energy use and transport to process efficiency.”

EUDRAGIT® polymers are polymethacrylates suitable for a wide range of drug delivery applications. Used individually or in combination, they enable virtually any target release profile, including immediate, delayed and sustained release. In addition, selected EUDRAGIT® grades can be used for solubility enhancement of poorly soluble drug substances. They are compatible with all relevant processing technologies, including hot melt extrusion and spray drying.

LCA data is integral to Evonik Health Care’s sustainability strategy, helping customers develop effective medications and treatments while minimizing environmental impacts. Evonik Health Care has the ambition to be climate neutral in Scope 1 and 2 emissions and generate more than 70 percent of its portfolio with Next Generation Solutions by 2030.

Further information:

EUDRAGIT® functional film coating polymers

Evonik: Leading beyond chemistry

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €14.1 billion and earnings (adjusted EBITDA) of €1.9 billion in 2025. The common motivation of the approximately 31,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.

About Custom Solutions

The Custom Solutions segment focuses on innovation-driven, tailor-made solutions for customers in specific growth markets. These solutions include additives for coatings, adhesives and sealants, polyurethane foams and lubricants, catalysts, and ingredients for the cosmetics, cleaning and pharmaceutical industries. In 2025, the segment generated sales of €5.4 billion with around 9,500 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.